Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Interest Income
Income earned on cash, deposits, and investments held by the company.
Sagimet Biosciences Inc.NASDAQ: SGMT
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income declines year over year
Q1 FY2026 interest income of $1.06M fell 37.1% year over year, ahead of the -90.5% change in trailing-twelve-month interest income. Over 3 fiscal years it compounded at +119.5% a year.
Context
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -37.1% holds above the trailing-twelve-month pace of -90.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 5.85M USD
- Year-over-year change
- -34.2%
- 4-year CAGR
- +287.3%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.85M | -34.2% |
| FY2024 | 2024-12-31 | 8.89M | +210.7% |
| FY2023 | 2023-12-31 | 2.86M | +417.2% |
| FY2022 | 2022-12-31 | 553K | +2026.9% |
| FY2021 | 2021-12-31 | 26K | — |
Interest Income vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's LTM Mar 2026 interest income of $800K is the 10th highest of the 11 companies compared; the peer median is $7.48M.
- Its year-over-year change of -90.5% is the 10th highest of 11, against a peer median of -38.0%.
- Over three fiscal years its annual growth of +119.5% compares with a peer median of +57.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $14.02M | -40.6% | +13.7% | — | |
| LTM Mar 2026 | $13.26M | -32.7% | — | 231.0% | |
| LTM Mar 2026 | $9.27M | -47.9% | +57.6% | 20.4% | |
| LTM Mar 2026 | $9.24M | -44.8% | +81.0% | 25.3% | |
| LTM Mar 2026 | $7.8M | -35.9% | +15.5% | 27.6% | |
| LTM Mar 2026 | $7.16M | +42.0% | +80.4% | 10.1% | |
ZURAZura Bio Limited | LTM Mar 2026 | $5.84M | -32.1% | +2131.8% | — |
| LTM Mar 2026 | $2.26M | -39.6% | -0.5% | 111.9% | |
| LTM Mar 2026 | $1.47M | -36.4% | +95.9% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $800K | -90.5% | +119.5% | — |
| LTM Mar 2026 | -$411.45M | -18576.2% | +44.2% | — | |
| Peer median (excluding SGMT) | $7.48M | -38.0% | +57.6% | 26.5% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 2M | 0 | 0 |
| Gross Margin | — | — | 100.0% | — | — |
| Research & Development | 19.34M | 24.92M | 19.78M | 38.44M | 39.05M |
| Selling, General & Admin | 4.38M | 6.14M | 12.96M | 16.01M | 17.84M |
| Operating Expenses | 23.72M | 31.06M | 32.74M | 54.45M | 56.89M |
| Depreciation & Amortization | 0 | 130K | 0 | 0 | 0 |
| EBITDA | (24.44M) | (30.37M) | (27.88M) | (45.57M) | (51.04M) |
| EBITDA Margin | — | — | -1393.8% | — | — |
| Operating Income | (23.72M) | (31.06M) | (30.74M) | (54.45M) | (56.89M) |
| Operating Margin | — | — | -1537.0% | — | — |
| Interest Income | 26K | 553K | 2.86M | 8.89M | 5.85M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (723K) | 556K | 2.86M | 8.89M | 5.85M |
| Income Before Tax | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Pre-Tax Margin | — | — | -1393.8% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Net Margin | — | — | -1393.8% | — | — |
| EPS (Basic) | (1.10) | (1.38) | (1.53) | (1.45) | (1.58) |
| EPS (Diluted) | (1.10) | (1.38) | (1.53) | (1.45) | (1.58) |
| Weighted Avg Shares | 22.17M | 22.17M | 18.19M | 31.35M | 32.35M |
| Weighted Avg Shares (Diluted) | 22.17M | 22.17M | 18.19M | 31.35M | 32.35M |
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.